Related Experiment Videos
[Recent progress in the management of malignant lymphoma]
1Dept. of Medicine III, Hamamatsu University School of Medicine, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 1, 1997
Summary
Recent lymphoma reviews cover the controversial REAL classification and established mantle cell lymphoma. Gastric MALT lymphoma regression with H. pylori eradication and new therapies for B cell and aggressive lymphomas are discussed.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Recent advancements in lymphoma classification and treatment necessitate a review of current knowledge.
- The clinical utility of the REAL classification for lymphoid neoplasms remains a subject of discussion.
- Understanding specific lymphoma subtypes, like mantle cell and gastric MALT lymphoma, is crucial for effective management.
Purpose of the Study:
- To review recent developments in lymphoma classification and treatment strategies.
- To discuss the prognostic implications of mantle cell lymphoma within the REAL classification.
- To explore the role of Helicobacter pylori in gastric MALT lymphoma and its treatment implications.
Main Methods:
- Literature review of recent lymphoma-related topics.
- Analysis of histopathological classifications, including the REAL classification.
- Evaluation of therapeutic approaches for various lymphoma subtypes.
Main Results:
- Mantle cell lymphoma is a well-established entity with an intermediate prognosis.
- Eradication of Helicobacter pylori can lead to regression of gastric MALT lymphoma.
- New therapies, including purine nucleoside analogs and high-dose chemoradiotherapy, show promise for specific lymphoma types.
Conclusions:
- The REAL classification's clinical usefulness is debated, but mantle cell lymphoma is recognized.
- Anti-H. pylori treatment is recommended for gastric MALT lymphoma.
- Risk-stratified therapy using the international prognostic index and novel agents improves outcomes for lymphoma patients.